Chlorozotocin

Drug Overview

Chlorozotocin is a highly specialized chemotherapy medication designed to fight certain types of cancer. It belongs to an older class of cancer-fighting drugs known as nitrosoureas. While it is not a widely used, everyday medication, it has played an important role in cancer research and the treatment of very specific tumors.

Because it has a sugar molecule (glucose) attached to it, chlorozotocin has some characteristics of a “Targeted Therapy.” The sugar helps guide the medicine directly to cells that absorb a lot of glucose, such as tumors in the pancreas.

Here are the key details about this medication:

• Generic Name: Chlorozotocin (often shortened to CHLZ or DCNU).
• US Brand Names: Mostly known by its generic name or early research names (like Dome or NSC-178248), as it is primarily a historical and investigational drug.
• Drug Class: Alkylating Agent / Nitrosourea.
• Route of Administration: Intravenous (IV) injection (given directly into a vein).
• FDA Approval Status: Chlorozotocin is an investigational and historical drug. It does not currently have standard FDA approval for widespread commercial use. Instead, it has been used under strict medical supervision in clinical trials and special treatment programs.

What Is It and How Does It Work? (Mechanism of Action)

To understand chlorozotocin, it helps to know how cancer cells grow. Cancer cells divide and multiply very quickly. To do this, they need to constantly copy their DNA (the instruction manual inside the cell).

Chlorozotocin stops this process at the molecular level through a process called “alkylation.” Here is how it works:

• Entering the Cell: Chlorozotocin is unique because it is linked to a glucose (sugar) molecule. Cancer cells, especially those in the pancreas, are hungry for sugar. The drug uses this sugar as a “Trojan horse” to easily enter the cell through special doorways called glucose transporters.
• Breaking the DNA: Once inside the nucleus (the control center of the cell), the drug attaches an “alkyl group” to the DNA.
• Creating Roadblocks (Cross-linking): The drug creates strong chemical bridges, known as cross-links, between the two strands of DNA. Imagine putting superglue on a zipper; the DNA can no longer unzip to copy itself.
• Cell Death: Because the cancer cell cannot copy its DNA, it cannot divide. The DNA strands eventually break, and the cancer cell dies.

Unlike other drugs in its class, chlorozotocin is designed to cause less harm to the bone marrow (where white blood cells are made), making it a unique tool for doctors.

FDA-Approved Clinical Indications

Because chlorozotocin is an investigational drug, it does not have standard FDA-approved indications for everyday use. However, it has been heavily studied and used in clinical trials for the following areas:

Oncological uses (in clinical trials):

• Pancreatic Neuroendocrine Tumors (PanNETs): Used to treat cancers of the islet cells in the pancreas.
• Melanoma: Used in trials to treat advanced skin cancer.
• Lung Cancer: Tested in patients with non-small cell lung cancer.
• Gastrointestinal Cancers: Used to slow the growth of tumors in the digestive tract.

Non-oncological uses:

• There are no approved non-oncological uses for humans.

Dosage and Administration Protocols

Because chlorozotocin is a powerful chemotherapy drug, it is given carefully by trained medical staff in a hospital or clinic.

Dose Adjustments: Chlorozotocin is processed by the liver and cleared from the body by the kidneys. If a patient has renal (kidney) or hepatic (liver) insufficiency, the doctor must lower the dose or delay treatment to prevent the medicine from building up to dangerous levels in the body.

Clinical Efficacy and Research Results

Because chlorozotocin is an older medication, much of the most active research happened before the 2020s. Current research between 2020 and 2025 mostly involves looking back at historical data to see how older drugs compare to modern therapies.

• Tumor Shrinkage: Historical trials showed that chlorozotocin could successfully stabilize the disease or cause partial tumor shrinkage in a subset of patients with advanced pancreatic tumors and melanoma.
• Survival Rates: While we cannot apply broad modern survival rates to this specific drug today, research shows that nitrosourea drugs (like chlorozotocin) paved the way for modern pancreatic cancer treatments. For patients who responded to the drug, doctors noted improved disease stabilization, giving them more time before the cancer started growing again.
• Ongoing Research: Today, researchers study the molecular structure of chlorozotocin to help design newer, safer cancer drugs that target tumors without harming healthy cells.

Safety Profile and Side Effects

Like most chemotherapy drugs, chlorozotocin affects healthy cells alongside cancer cells, which causes side effects.

Black Box Warning Equivalent: While it does not have a modern FDA Black Box Warning label due to its investigational status, it carries severe warnings for bone marrow suppression (dangerously low blood cells), liver damage, and the risk of causing secondary cancers later in life.

Common side effects (>10%):

• Thrombocytopenia (Low Platelets): A drop in the blood cells that help blood clot. This usually happens about 4 weeks after the injection and can cause easy bruising or bleeding.
• Nausea and Vomiting: Mild to moderate upset stomach shortly after the infusion.
• Elevated Liver Enzymes: Blood tests may show that the liver is working harder than usual, though this is usually mild and temporary.

Serious adverse events:

• Hepatotoxicity: Severe liver damage.
• Nephrotoxicity: Kidney damage that can affect how the body filters waste.
• Secondary Malignancies: Because it alters DNA, there is a risk that it could cause a different type of cancer years after treatment.

Management Strategies:

• If nausea occurs, doctors will prescribe anti-nausea medications before the treatment begins.
• If a patient’s platelet count drops too low, doctors will delay the next dose or provide a platelet blood transfusion to prevent dangerous bleeding.

Research Areas

While chlorozotocin is primarily known as a cancer drug, it has a very important connection to stem cell and regenerative medicine research. Because chlorozotocin specifically targets the insulin-producing “beta cells” in the pancreas, scientists safely use it in laboratory animal models to mimic human diabetes. By temporarily creating a diabetic environment in the lab, researchers can test brand-new stem cell therapies. They implant healthy, lab-grown stem cells into the models to see if the new cells can successfully grow, replace the damaged pancreas cells, and cure diabetes.

Patient Management and Practical Recommendations

To keep patients safe, strict rules must be followed before and during treatment.

Pre-treatment tests to be performed:

• Complete Blood Count (CBC): To ensure platelet and white blood cell levels are high enough to safely receive the drug.
• Liver and Kidney Panels: Blood tests to ensure these organs are healthy enough to process the medicine.
• Pregnancy Test: The drug can cause severe harm to an unborn baby, so a negative test is required for women of childbearing age.

Precautions during treatment:

• Patients will be monitored closely by nurses during the IV push to watch for allergic reactions or pain at the injection site.
• Because of the delayed effect on blood platelets, patients must be very careful to avoid cuts, falls, or injuries for several weeks after receiving the drug.

“Do’s and Don’ts” list:

• DO attend all follow-up appointments for blood tests. This is the only way your doctor can check your platelet levels.
• DO tell your doctor immediately if you notice unusual bruising, bleeding gums, or a fever.
• DO use a soft-bristled toothbrush and an electric razor to avoid accidental bleeding.
• DON’T take aspirin or ibuprofen without asking your doctor, as these can make bleeding worse.
• DON’T become pregnant or father a child while taking this medication. Reliable birth control is strictly required.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Chlorozotocin is an investigational diagnostic and therapeutic agent and is not currently approved by the US Food and Drug Administration (FDA) for general, widespread clinical use. It has historically been available only through participation in approved clinical trials or special access programs. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for specific medical therapies.